Growth Metrics

Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $733000.0.

  • Harvard Bioscience's Non-Current Deferred Tax Liability rose 367.75% to $733000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $733000.0, marking a year-over-year increase of 367.75%. This contributed to the annual value of $710000.0 for FY2024, which is 850.52% down from last year.
  • As of Q3 2025, Harvard Bioscience's Non-Current Deferred Tax Liability stood at $733000.0, which was up 367.75% from $734000.0 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Non-Current Deferred Tax Liability registered a high of $2.4 million during Q2 2022, and its lowest value of $546000.0 during Q1 2023.
  • For the 5-year period, Harvard Bioscience's Non-Current Deferred Tax Liability averaged around $1.0 million, with its median value being $764000.0 (2024).
  • As far as peak fluctuations go, Harvard Bioscience's Non-Current Deferred Tax Liability skyrocketed by 5438.93% in 2022, and later crashed by 7251.75% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Non-Current Deferred Tax Liability stood at $1.6 million in 2021, then plummeted by 62.13% to $590000.0 in 2022, then skyrocketed by 31.53% to $776000.0 in 2023, then dropped by 8.51% to $710000.0 in 2024, then rose by 3.24% to $733000.0 in 2025.
  • Its Non-Current Deferred Tax Liability was $733000.0 in Q3 2025, compared to $734000.0 in Q2 2025 and $717000.0 in Q1 2025.